zadnja posodobitev :
19/11/2024
Antimikotik   Amphotericin B lipid complex  
Brizgalka
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost način aplikacije Viri pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Abelcet Argentina, Avstralija, Avstrija, Belgija, Brazilija, Danska, Finska, Francija, Grčija, Irska, Italija, Kanada, Luksemburg, Madžarska, Malezija, Mehika, Nemčija, Nizozemska, Norveška, Peru, Portugalska, Romunija, Španija, Švedska, Velika Britanija, Združene države Amerike
Viri   Brizgalka   Viri : Amphotericin B lipid complex  
Tip objava
1510 Knjiga AHFS Formulary service 2000 Bethesda - 3546 p
2247 časopis Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 časopis Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3254 časopis Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Traduction Laboratorij Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3644 Traduction Laboratorij Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3828 poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 časopis Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44

  Mentions Légales